Cost-effectiveness of quantiferon testing before initiation of biological therapy in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 19, Issue 11, 2013, Pages 2444-2449

  Swaminath, Arun ^a   Bhadelia, Nahid ^b   Wang, Y Claire ^c  

^a Department of Medicine   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Department of Medicine   (United States)

Author keywords

Cost effectiveness; IBD; Interferon gamma release assay; Latent tuberculosis reactivation

Indexed keywords

GAMMA INTERFERON; IMMUNOMODULATING AGENT; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; ASSAY; BIOLOGICAL THERAPY; COST EFFECTIVENESS ANALYSIS; CYTOKINE RELEASE; DECISION TREE; ENTERITIS; HUMAN; INTERMETHOD COMPARISON; LATENT TUBERCULOSIS; OUTCOMES RESEARCH; POSTPRIMARY TUBERCULOSIS; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; TUBERCULIN TEST;

ADULT; COST-BENEFIT ANALYSIS; CROHN DISEASE; DECISION TREES; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MASS SCREENING; MODELS, ECONOMETRIC; PROGNOSIS; TUBERCULIN TEST;

EID: 84888232718     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e31829f008f     Document Type: Article

References (34)

1. Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 2004;50:372-379.
2. Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum. 2003;48:2122-2127.
3. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-1104.
4. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol. 2006;2:602-610.
5. Winthrop KL, Siegel JN, Jereb J, et al. Tuberculosis associated with therapy against tumor necrosis factor alpha. Arthritis Rheum. 2005;52:2968-2974.
6. Mandell GL, Bennett JE, Dolin R. Mandell, Douglas, and Bennetts Principles and Practice of Infectious Diseases. Philadelphia, PA: Churchill Livingstone/Elsevier; 2010.
7. Mow WS, Abreu-Martin MT, Papadakis KA, et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol. 2004;2:309-313.
8. Kobashi Y, Mouri K, Obase Y, et al. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients. Eur Respir J. 2007;30: 945-950.
9. Schoepfer AM, Flogerzi B, Fallegger S, et al. Comparison of interferongamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol. 2008;103: 2799-2806.
10. Woeltje KF, Mathew A, Rothstein M, et al. Tuberculosis infection and anergy in hemodialysis patients. Am J Kidney Dis. 1998;31:848-852.
11. Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev. 2008;8:147-152.
12. Mazerek GH, Jereb J, Vernon A, et al. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection- United States, 2010. MMWR Morb Mortal Wkly Rep. 2010;59:1-25.
13. Qumseya BJ, Ananthakrishnan AN, Skaros S, et al. QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflamm Bowel Dis. 2011;17:77-83.
14. Matulis G, Juni P, Villiger PM, et al. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis. 2008;67:84-90.
15. Sellam J, Hamdi H, Roy C, et al. Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis. 2007;66:1610-1615.
16. Papay P, Eser A, Winkler S, et al. Factors impacting the results of interferon-gamma release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:84-90.
17. Belard E, Semb S, Ruhwald M, et al. Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis. 2011;17:2340-2349.
18. Soborg B, Ruhwald M, Hetland ML, et al. Comparison of screening procedures for Mycobacterium tuberculosis infection among patients with inflammatory diseases. J Rheumatol. 2009;36:1876-1884.
19. Vassilopoulos D, Tsikrika S, Hatzara C, et al. Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy. Clin Vaccine Immunol. 2011;18:2102-2108.
20. Bartalesi F, Vicidomini S, Goletti D, et al. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J. 2009;33:586-593.
21. Bocchino M, Matarese A, Bellofiore B, et al. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect Dis. 2008;27:907-913.
22. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax. 2005;60:800-805.
23. Horsburgh CR Jr, Rubin EJ. Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med. 2011;364:1441-1448.
24. Van Assche G, Lewis JD, Lichtenstein GR, et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohns and Colitis Organisation: safety. Am J Gastroenterol. 2011;106:1594-1602; quiz 1593, 1603.
25. Bennett DE, Courval JM, Onorato I, et al. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. Am J Respir Crit Care Med. 2008;177: 348-355.
26. Cobelens FG, Egwaga SM, van Ginkel T, et al. Tuberculin skin testing in patients with HIV infection: limited benefit of reduced cutoff values. Clin Infect Dis. 2006;43:634-639.
27. Aziz MA, Wright A, Laszlo A, et al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): An updated analysis. Lancet. 2006;368:2142-2154.
28. Dye C, Scheele S, Dolin P, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country.WHO Global Surveillance and Monitoring Project. JAMA. 1999;282:677-686.
29. Linas BP, Wong AY, Freedberg KA, et al. Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med. 2011;184:590-601.
30. Pai M, Riley LW, Colford JM Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: A systematic review. Lancet Infect Dis. 2004; 4:761-776.
31. Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis. 2006;43:717-722.
32. Denis B, Lefort A, Flipo RM, et al. Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate antituberculous treatment. Clin Microbiol Infect. 2008;14:183-186.
33. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163:1009-1021.
34. Aberra FN. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Gastroenterology. 2009;136:1453-1455; discussion 1455.